Desmoid tumor, synovial sarcoma, giant cell tumor, chordoma
Conditions
Interventions
Intervention group:Implantation of HANPs
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. The patient's gender is not limited, aged 18-65 years. 2. The pathological diagnosis is consistent with any of desmoid tumor, synovial sarcoma, chordoma and giant cell tumor, whether or not it is a recurrent tumor. 3. En bloc resection should be applied for desmoid tumor, synovial sarcoma and chordoma. 4. The method of excision of giant cell tumor should be curretage and inactivation of the tumor cavity, which can be supplemented with bone cement or/and bone graft or/and support, with or without internal fixation. 5. Patients participate voluntarily, sign written informed consent and willing to cooperate closely with doctors to comply with all research requirements, including participation in all follow-up and evaluation, and postoperative rehabilitation programs.
Exclusion criteria
Exclusion criteria: 1. Segment resection was performed for giant cell tumor. 2. Severe heart, liver, kidney, lung and brain dysfunction. 3. Pregnant women and lactating women. 4. Systemic connective tissue disease. 5. Uncontrollable diabetes. 6. History of autoimmune disease, HIV infection, immunosuppressive disorder or taking immunosuppressant. 7. History of syphilis (Treponema pallidum). 8. Active hepatitis B or C infection, and verified antigens. 9. History of other cancers in the past 5 years. 10. Metastasis occurs and life expectancy is less than 1 year. 11. Participating or participated in any other clinical research within 3 months before the screening visit. 12. Current or recent illegal drugs or alcohol abuse or dependence drugs. 13. Psychiatric or cognitive impairment, which the investigator believes will impair the patient's ability to comply with the research requirements. 14. The patient has any other conditions that the investigator believes will make the patient unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence rate;Adverse event; | — |
Secondary
| Measure | Time frame |
|---|---|
| Metastatic rate;Overall survival; | — |
Countries
PR China
Contacts
Public ContactTu Chongqi
West China Hospital, Sichuan University
Outcome results
None listed